文献速递血栓与止血

癌症患者孤立性远端深静脉血栓与近端静脉血栓栓塞症的临床结局比较:克利夫兰诊所经验

Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience.
PubMed 文献 · J Thromb Haemost · 2019-12-30

该前瞻性队列纳入2014年8月至2018年5月转诊至癌症相关血栓门诊的患者,比较癌症相关孤立性远端深静脉血栓(IDDVT)与近端静脉血栓栓塞症(VTE)的临床结局。1100例转诊患者中分析124例IDDVT与178例近端VTE事件,倾向性评分匹配后每组96例。

要点

  • 癌症相关IDDVT与近端VTE的复发性VTE风险无显著差异。
  • 匹配后两组总生存无差异,大出血与后续住院情况相似。
  • 癌症相关IDDVT的治疗应与近端事件保持一致。

核心结论

  • 癌症合并IDDVT患者的结局与近端VTE患者相似,包括复发率和总生存。
  • 研究提示癌症相关IDDVT的治疗应参照近端VTE的治疗策略。

研究设计与样本

  • 前瞻性评估2014年8月至2018年5月转诊至癌症相关血栓门诊的患者队列。
  • 1100例转诊患者中分析124例IDDVT与178例近端VTE事件。
  • 采用倾向性评分匹配减少混杂偏倚,匹配后每组96例。

主要发现

  • 后续住院与大出血事件在近端VTE与IDDVT患者间相似。
  • 未匹配与匹配分析中复发性VTE和总生存均未见差异。

临床怎么用

  • 对癌症相关IDDVT应按近端VTE同等对待进行抗凝治疗决策。
  • 癌症患者IDDVT随访中需关注复发、出血与再住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies suggest isolated distal deep vein thrombosis (IDDVT) has a self-limited clinical course. However, these studies excluded cancer patients, who remain a high-risk population. In addition, studies to evaluate the long-term clinical outcomes of IDDVT in cancer patients have been limited. Here, we report outcomes from our experience in treating cancer-associated IDDVT versus proximal venous thromboembolism (VTE). METHODS: We prospectively evaluated a cohort of patients referred to our cancer-associated thrombosis clinic from August 2014 through May 2018. We compared clinical characteristics, anticoagulation prescription, VTE recurrence, overall survival, major bleeding, and subsequent hospital admission between cancer patients with IDDVT and proximal VTE. A propensity score matching method was used to reduce bias from confounding variables. RESULTS: Of 1100 patients referred to the clinic, 124 IDDVT and 178 proximal VTE events were analyzed. After propensity score matching, 96 patients were included in each cohort. There was no difference in the rate of recurrent VTE between cancer patients with proximal VTE vs IDDVT, with or without matching (matched: hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.31-1.92; P = .58). There was no difference in overall survival between cancer patients with proximal VTE vs. IDDVT with or without matching (matched: HR, 1.18; 95% CI, 0.77-1.82; P = .45). Furthermore, subsequent hospital admissions and major bleeding events were similar between patients with proximal VTE events versus IDDVT. CONCLUSIONS: Cancer patients with IDDVT have similar outcomes as their proximal counterparts, including rate of recurrence and overall survival. These findings suggest treatment of cancer-associated IDDVT should mirror treatment of proximal events.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Poudel SK, Park DY, Jia X, et al. Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. J Thromb Haemost. 2019. PMID: 31808607. doi:10.1111/jth.14700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。